Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
AVR Stock Chart & Stats
$5.44
-$0.12(-2.09%)
At close: 4:00 PM EST
$5.44
-$0.12(-2.09%)
Day’s Range― - ―
52-Week Range$2.34 - $6.95
Previous Close$5.88
Volume157.53K
Average Volume (3M)151.40K
Market Cap
$528.94M
Enterprise Value$189.84M
Total Cash (Recent Filing)$12.58M
Total Debt (Recent Filing)$2.28M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
May 19, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding97,232,056
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue99.23
Enterprise Value/Gross Profit141.25
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$15.75Price Target Upside189.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$8.58M
Bulls Say, Bears Say
Bulls Say
Strategic Medtronic FinancingThe $320M financing, including a $90M strategic equity investment from a Medtronic subsidiary, materially extends runway to execute the PARADIGM pivotal trial and early commercialization steps. This durable capital reduces near-term funding risk and aligns a major industry partner with execution and market access over coming quarters.
Pivotal PARADIGM Randomized TrialA head‑to‑head, randomized pivotal study of ~1,000 patients can generate high‑quality clinical evidence required for regulatory approval and clinician adoption. Positive trial results would be a durable competitive differentiator, facilitating market access, reimbursement discussions, and long‑term commercial positioning in TAVR.
Sharp Gross Margin ImprovementA roughly 70% gross margin in 2025 indicates favorable product economics or improved manufacturing efficiency. If sustained as volumes scale post‑commercialization, high gross margins support margin sustainability, help absorb fixed costs and R&D investments, and improve long‑term profitability potential.
Bears Say
Declining Revenue TrendRevenue has trended meaningfully lower over several years, shrinking the top line to levels that cannot support current operating cost structure. Persistent revenue decline undermines the firm's ability to scale, leverage fixed costs, and reach self‑sustaining operations without sustained commercial uptake or new revenue streams.
Severe And Rising Cash BurnConsistent, large negative operating and free cash flow—notably ~-$77.8M in 2025—creates structural dependence on external financing. Even with recent capital, ongoing burn risks repeated dilution, limits flexibility for R&D or commercialization spending, and makes execution highly contingent on trial outcomes and financing access.
Dilution And Governance Constraints From Equity DealThe equity offering granted Medtronic subsidiary registration, participation and investor rights, transfer limits, a non‑voting observer and structured negotiation rights on acquisitions. These terms materially dilute existing holders and may constrain future strategic and capital decisions, reducing independent flexibility over the medium term.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $6.95 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $528.94M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
Anteris Technologies Global Corp.’s upcoming earnings report date is May 19, 2026 which is in 39 days.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on Mar 18, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.503 by -$0.237.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate is -0.16.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 97,232,056 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.503. Following the earnings report the stock price went down -1.34%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (189.52% Upside)
$15.75 (189.52% Upside)
Hedge Fund Trend
Decreased
By 29.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
-2462.70%
Trailing 12-Months
Asset Growth
-9.61%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$15.75
▲(189.52% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
14.01% Insiders
1.60% Mutual Funds
13.19% Other Institutional Investors
68.91% Public Companies and
Individual Investors